Editorial: Unifying the genetics,co-morbidities and management of COPD

Abstract

References

Agusti, A.G. (2005). Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2(4): 367-370; discussion 371-372.

Bruce, C. and Thomas, P.S. (2005). The effect of marimastat, a metalloprotease inhibitor, on allergen-induced asthmatic hyper-reactivity. Toxicol Appl Pharmacol 205(2): 126-132.

Calverley, P.M. , Burge, P.S. , Spencer, S. , Anderson, J.A. and Jones, P.W. (2003). Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 58(8): 659-664.

Celli, B.R. (2006). Chronic obstructive pulmonary disease: from unjustified nihilism to evidence-based optimism. Proc Am Thorac Soc 3(1): 58-65.

Chasman, D.I. , Posada, D. , Subrahmanyan, L. , Cook, N.R. , Stanton Jr, V.P. and Ridker, P.M. (2004). Pharmacogenetic study of statin therapy and cholesterol reduction. Jama 291(23): 2821-2827.

Compton, C.H. , Gubb, J. , Nieman, R. , Edelson, J. , Amit, O. , Bakst, A. et al. (2001). Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 358(9278): 265-270.

Curkendall, S.M. , DeLuise, C. , Jones, J.K. , Lanes, S. , Stang, M.R. , Goehring Jr, E. et al. (2006). Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 16(1): 63-70.

Decramer, M. , Rutten-van Molken, M. , Dekhuijzen, P.N. , Troosters, T. , van Herwaarden, C. , Pellegrino, R. et al. (2005). Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 365(9470): 1552-1560.

Demeo, D.L. , Hersh, C.P. , Hoffman, E.A. , Litonjua, A.A. , Lazarus, R. , Sparrow, D. et al. (2007). Genetic determinants of emphysema distribution in the national emphysema treatment trial. Am J Respir Crit Care Med 176(1): 42-48.

10.

Fabbri, L. , Pauwels, R.A. and Hurd, S.S. (2004). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary updated 2003. Copd 1(1): 105-141; discussion 103-104.

11.

Gompertz, S. and Stockley, R.A. (2002). A randomized, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD. Chest 122(1): 289-294.

12.

Hegab, A.E. , Sakamoto, T. , Saitoh, W. , Massoud, H.H. , Massoud, H.M. , Hassanein, K.M. et al. (2004). Polymorphisms of IL4, IL13, and ADRB2 genes in COPD. Chest 126(6): 1832-1839.

13.

Homma, S. , Sakamoto, T. , Hegab, A.E. , Saitoh, W. , Nomura, A. , Ishii, Y. et al. (2006). Association of phosphodiesterase 4D gene polymorphisms with chronic obstructive pulmonary disease: relationship to interleukin 13 gene polymorphism. Int J Mol Med 18(5): 933-939.

14.

Huang, S.L. , Su, C.H. and Chang, S.C. (1997). Tumor necrosis factor-alpha gene polymorphism in chronic bronchitis. Am J Respir Crit Care Med 156(5): 1436-1439.

15.

Israel, E. , Drazen, J.M. , Liggett, S.B. , Boushey, H.A. , Cherniack, R.M. , Chinchilli, V.M. et al. (2000). The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 162(1): 75-80.

16.

Ito, I. , Nagai, S. , Handa, T. , Muro, S. , Hirai, T. , Tsukino, M. et al. (2005). Matrix metalloproteinase-9 promoter polymorphism associated with upper lung dominant emphysema. Am J Respir Crit Care Med 172(11): 1378-1382.

17.

Jeffery, P.K. , Venge, P. , Gizycki, M.J. , Egerod, I. , Dahl, R. and Faurschou, P. (2002). Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study. Eur Respir J 20(6): 1378-1385.

18.

Mahler, D.A. , Huang, S. , Tabrizi, M. and Bell, G.M. (2004). Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest 126(3): 926-934.

19.

Mao, J.T. , Goldin, J.G. , Dermand, J. , Ibrahim, G. , Brown, M.S. , Emerick, A. et al. (2002). A pilot study of all-trans-retinoic acid for the treatment of human emphysema. Am J Respir Crit Care Med 165(5): 718-723.

20.

Rabe, K.F. , Bateman, E.D. , O'Donnell, D. , Witte, S. , Bredenbroker, D. and Bethke, T.D. (2005). Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 366(9485): 563-571.

21.

Rennard, S.I. , Fogarty, C. , Kelsen, S. , Long, W. , Ramsdell, J. , Allison, J. et al. (2007). The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175(9): 926-934.

22.

Rennard, S.I. , Schachter, N. , Strek, M. , Rickard, K. and Amit, O. (2006). Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest 129(1): 56-66.

23.

Salpeter, S.R. , Buckley, N.S. , Ormiston, T.M. and Salpeter, E.E. (2006). Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 144(12): 904-912.

24.

Sandford, A.J. , Chagani, T. , Weir, T.D. , Connett, J.E. , Anthonisen, N.R. and Pare, P.D. (2001). Susceptibility genes for rapid decline of lung function in the lung health study. Am J Respir Crit Care Med 163(2): 469-473.

25.

Schmidt, M.I. , Duncan, B.B. , Sharrett, A.R. , Lindberg, G. , Savage, P.J. , Offenbacher, S. et al. (1999). Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 353(9165): 1649-1652.

26.

Seitz, M. , Wirthmuller, U. , Moller, B. and Villiger, P.M. (2007). The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 46(1): 93-96.

27.

Sevenoaks, M.J. and Stockley, R.A. (2006). Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity-a common inflammatory phenotype? Respir Res 7: 70.

28.

Sin, D.D. , Man, J.P. and Man, S.F. (2003). The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med 114(1): 10-14.

29.

Soyseth,V. , Brekke, P.H. , Smith, P. and Omland, T. (2007). Statin use is associated with reduced mortality in COPD. Eur Respir J 29(2): 279-283.

30.

Sparano, J.A. , Bernardo, P. , Stephenson, P. , Gradishar, W.J. , Ingle, J.N. , Zucker, S. et al. (2004). Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol 22(23): 4683-4690.

31.

Vozarova, B. , Fernandez-Real, J.M. , Knowler, W.C. , Gallart, L. , Hanson, R.L. , Gruber, J.D. et al. (2003). The interleukin-6 (-174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in Native Americans and Caucasians . Hum Genet 112(4): 409-413.

32.

Wechsler, M.E. , Lehman, E. , Lazarus, S.C. , Lemanske Jr, R.F. , Boushey, H.A. , Deykin, A. et al. (2006). beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 173(5): 519-526.

33.

Wilk, J.B. , Walter, R.E. , Laramie, J.M. , Gottlieb, D.J. and O'Connor, G.T. (2007). Framingham Heart Study genome-wide association: results for pulmonary function measures. BMC Med Genet 8 Suppl 1: S8.

34.

Wood, A.M. and Stockley, R.A. (2006). The genetics of chronic obstructive pulmonary disease. Respir Res 7: 130.

35.

Wtccc (2007). Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447(7145): 661-678.

36.

Yasmin , McEniery, C.M. , O'Shaughnessy, K.M. , Harnett, P. , Arshad, A. , Wallace, S. et al. (2006). Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals. ArteriosclerThromb Vasc Biol 26(8): 1799-1805.